Major Influenza Pandemic Threat is now Preventable and Treatable with Canopus BioPharma, Inc.'s Aerosol Statin Formulation

LOS ANGELES--(BUSINESS WIRE)--Canopus BioPharma Inc. (OTCPK: CBIA) today announced it has commissioned a team of experts led by Dr. Akihiro Shimosaka, to assist with its plans for major collaborations to license, manufacture and distribute its H1N1 Swine flu statin antiviral. This team is currently in negotiations with the Office of Disease Control and Emergency Response, the CDC and the SFDA in China with a view to initiating large scale clinical trials and gaining marketing approval on behalf of Canopus BioPharma.